Clinical trials located in


Madrid city is located in Spain. Currently, 20 clinical trials are being conducted in this city.

Madrid, Spain’s vibrant capital, stands at the heart of the Iberian Peninsula. Founded in the 9th century, it’s a city rich in history and culture. Madrid is home to the Royal Palace, the largest royal palace in Western Europe, and the Prado Museum, showcasing one of the finest collections of European art. The city is also known for its lively squares like the Plaza Mayor and Puerta del Sol. Madrid’s Buen Retiro Park, an oasis of peace, contrasts with its bustling Gran Vía, the street that never sleeps.

  • CT-EU-00121786

    Gene therapy safety and efficacy study for adults with Gaucher Disease Type 1

    This clinical trial is a groundbreaking study aimed at patients with Gaucher Disease Type 1. It is the first of its kind to explore the use of a gene therapy called FLT201. The study is open-label, meaning both the researchers and participants know what treatment is being administered. The primary goals are to assess the safety, tolerability, and efficacy of FLT201 in adult patients.

    The trial will investigate how different doses of FLT201 affect the levels of an enzyme called glucocerebrosidase (GCase). This enzyme is crucial for breaking down certain substances in the body, and its deficiency leads to the symptoms of Gaucher Disease. By increasing GCase activity and concentration, the study aims to see if FLT201 can improve the clinical symptoms of the disease by reducing and preventing the buildup of harmful substances in cells.

    One of the key aspects being monitored is the incidence of treatment-emergent adverse events, which includes any side effects that occur after the treatment is administered. These adverse events will be categorized as mild, moderate, or severe and will be tracked from the first day of dosing through the final follow-up visit at Week 38.

  • Study of LY3884961 for safety and tolerability in Gaucher Disease patients

    Gaucher disease is a rare genetic disorder that affects how certain fats are stored and processed in the body. It can lead to a variety of symptoms, including problems with the spleen, liver, bones, and sometimes the nervous system. This study aims to explore a new therapy called LY3884961, which is a special type of treatment designed to target and potentially correct the underlying issues in Gaucher disease.

    This study is designed to determine how safe and tolerable LY3884961 is for adults with peripheral (outside the nervous system) manifestations of Gaucher disease. This involves giving a single dose of LY3884961 through an intravenous infusion (a drip).

    The study is structured in phases, starting with a small number of participants to find the right dose level. Initially, three dose levels will be tested with three patients in each group, followed by an expansion to possibly include six more patients. Each participant will go through a screening period lasting up to 45 days before the treatment.

    After receiving the treatment, participants will be closely monitored for the first 18 months to see how their bodies react to LY3884961. This involves checking various health markers and ensuring no harmful effects. After this period, participants will continue to be observed for an additional 42 months to further track their safety and any lasting effects or changes in their health.

  • Study comparing Giredestrant and Fulvestrant with CDK4/6 Inhibitors for advanced breast cancer

    This study focuses on a type of advanced breast cancer known as Estrogen Receptor-Positive (ER+), HER2-Negative breast cancer. This kind of cancer is driven by hormones and does not have high levels of the HER2 protein. The study aims to evaluate the effectiveness and safety of a new drug called Giredestrant compared to an existing drug called Fulvestrant. Both drugs will be combined with one of three medicines that inhibit proteins in cancer cells called CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib).

    In this study, participants will be randomly assigned to one of two groups. One group will receive Giredestrant and the other will receive Fulvestrant. Both groups will also receive one of the CDK4/6 inhibitors chosen by their doctor. These combinations are being tested to see which works better to stop the cancer from growing or spreading.

    The drugs involved include Giredestrant (RO7197597, RG6171, GDC-9545), Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, and LHRH Agonist (for pre/perimenopausal women and men).

    The goal is to find out if Giredestrant can provide better results and fewer side effects compared to Fulvestrant when both are combined with one of the CDK4/6 inhibitors. The study may involve regular tests and assessments to monitor the cancer’s progress and the patient’s response to the treatment.

    Participants will continue to receive the study drugs as long as they are benefiting from them and not experiencing unacceptable side effects. The study involves close monitoring to ensure the safety and well-being of all participants throughout the treatment period.

    • LHRH Agonist
    • Abemaciclib
    • Giredestrant
    • Palbociclib
    • Ribociclib
    • Fulvestrant
  • Safety and efficacy study of BA3021 for patients with lung cancer, breast cancer, melanoma, or head and neck cancer

    This clinical trial targets various types of cancer such as Non-Small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Melanoma, and Head and Neck Cancer. The therapy being assessed involves BA3021 (CAB-ROR2-ADC), a specialized drug designed to target cancer cells. Another drug, a PD-1 inhibitor, will also be used in one part of the study.

    The primary goal of this study is to evaluate the safety and effectiveness of BA3021, alone or in combination with a PD-1 inhibitor, in treating advanced solid tumors.

    This trial will be carried out in two phases:
    Phase 1 will focus on understanding the appropriate dose and its safety, while
    Phase 2 will evaluate how well the drug works alone or together with the PD-1 inhibitor.

    Participants will receive either BA3021 alone or BA3021 in combination with the PD-1 inhibitor. They will be monitored closely throughout the study to track their health and the drug’s effects on their cancer.

  • CT-EU-00068410

    A study of the treatment of advanced breast cancer with Giredestrant and the drug combination Phesgo

    The study is aimed at patients with locally advanced or metastatic breast cancer that is HER2-positive and ER-positive. HER2 and ER are receptors that can influence the growth of cancer cells. The aim of this study is to evaluate the effectiveness and safety of the combination of giredestrant and Phesgo compared with Phesgo alone after a run-in phase with Phaesgo and taxane-based chemotherapy.

    Phesgo is a combination containing pertuzumab, trastuzumab and hyaluronidase, administered subcutaneously every three weeks. Giredestrant is a capsule taken orally every day. Taxane chemotherapy may include drugs such as Docetaxel and Paclitaxel, which are given intravenously. The aim of the study is to compare how well these drug combinations work in preventing disease progression and improving patient survival.

    • hyaluronidase
    • Giredestrant
    • Pertuzumab
    • Trastuzumab
    • Paclitaxel
    • Docetaxel
  • CT-EU-00084342

    Efficacy and safety of MK-7684A and drug combinations in the treatment of selected malignancies in patients with advanced tumors

    The clinical trial covers various types of cancer such as cervical cancer, endometrial cancer (lining of the uterus), head and neck cancer, gallbladder cancer, cholangiocarcinoma, esophageal cancer, triple negative breast cancer, hepatocellular carcinoma, bladder cancer urinary tract, ovarian cancer and stomach cancer.

    The study is testing various therapies combining pembrolizumab and vibostolimab (designated MK-7684A), pembrolizumab alone and combinations with other anticancer drugs such as lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine and oxaliplatin.

    The aim of the study is to determine the safety, tolerability and preliminary effectiveness of various drug combinations in the treatment of selected advanced malignancies

    • Pembrolizumab
    • Pembrolizumab and Vibostolimab/ MK-7684A
    • Lenvatinib
    • Bevacizumab
    • Gemcitabine
    • Cisplatin
    • Carboplatin
    • Capecitabine
    • Oxaliplatin
    • 5-Fluorouracil
    • Paclitaxel
    • Docetaxel
  • Study of Aplitabart alone or with other treatments in patients with various cancers

    This clinical trial concerns various cancers including solid tumors, colorectal cancer, non-Hodgkin lymphoma, sarcoma, chondrosarcoma, small lymphocytic lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia.

    The main focus of this study is the investigation of a drug called aplitabart (IGM-8444). This drug will be tested alone and in combination with other medications, which include FOLFIRI (a combination chemotherapy regimen), bevacizumab (a targeted therapy also known as Avastin), birinapant (an investigational drug), venetoclax (a targeted therapy also known as Venclexta), docetaxel (a chemotherapy drug also known as Taxotere or Docefrez), gemcitabine (a chemotherapy drug also known as Gemzar), and azacitidine (a chemotherapy drug also known as VIDAZA). The purpose of the study is to determine the safety, tolerability, and how the body processes (pharmacokinetics) aplitabart when used alone or combined with these other drugs.

    There are two main parts of the study. Phase 1a consists of two stages: Dose escalation, where participants will receive increasing doses of aplitabart to determine the safest and most effective dose, and Expansion, where more participants will receive the best dose to see how well it works alone or with other drugs. Phase 1b will focus on colorectal cancer participants. It will be an open-label, randomized study where some participants will receive a combination of aplitabart, FOLFIRI, and bevacizumab, while others will receive only FOLFIRI and bevacizumab.

    All medications will be given intravenously (through a vein). Different tumor types will be included, such as various solid tumors, colorectal cancers, certain types of leukemia, and lymphomas.

    • Aplitabart (IGM-8444)
    • azacitidine
    • Bevacizumab (and approved biosimilars)
    • Birinapant
    • Gemcitabine
    • Venetoclax
    • Docetaxel
  • Study of the safety and effectiveness of GLSI-100 in patients with HER2-positive breast cancer

    The study concerns the treatment of patients with HER2/neu-positive breast cancer. Treatment will include GLSI-100 immunotherapy and comparison to placebo. GLSI-100 consists of GP2 peptide and GM-CSF, protein substances that are designed to strengthen the body’s immune response, i.e. natural protection against diseases.

    The aim of this study is to determine how effective and safe GLSI-100 therapy is compared to placebo in preventing breast cancer recurrence after standard treatment. The study is aimed at people at high risk of disease recurrence who have completed both preoperative and postoperative therapy based on trastuzumab, a drug used to treat breast cancer.

    The study will assess invasive breast cancer-free survival (i.e. the time from the first dose of the drug to the moment of disease recurrence or death from any cause), invasive disease-free survival (i.e. the time from the first dose of the drug to the moment of any disease recurrence or new cancer), remote disease (i.e. time until disease recurrence in a place other than the breast or death).

    The study also includes an assessment of the participants’ quality of life both at the beginning and over the next 36 months, as well as an analysis of the body’s immune response to treatment.

  • Study of Palazestrant or standard therapy in advanced ER+/HER2- breast cancer

    This clinical trial is for patients with advanced or metastatic breast cancer with hyperactivity of estrogen receptors (ER+) and no hyperactivity of HER2- receptors (advanced HER2- breast cancer). The therapy used in the study includes a new drug called palazestrant (OP-1250) and other standard endocrine therapies such as Fulvestrant or aromatase inhibitors (anastrozole, letrozole, exemestane).

    The aim of the study is to compare the effectiveness and safety of palazestrant (OP-1250) as monotherapy compared to the above-mentioned standard therapies in the treatment of this type of breast cancer.

    Patients in the study will be randomly assigned to one of the groups – one receiving palazestrant (OP-1250) and the other receiving one of the standard therapies (fulvestrant, anastrozole, letrozole or exemestane). The study will assess progression-free survival (the time from the start of treatment to the time the disease starts to progress again) and overall survival of participants (the time from the start of treatment to death from any cause).

    • Palazestrant
    • Fulvestrant
    • Anastrozole
    • Letrozole
    • Exemestane
  • CT-EU-00068643

    Study of the effects and safety of Inavolisib and Fulvestrant compared with Alpelisib and Fulvestrant in patients with advanced breast cancer

    The clinical trial is for breast cancer. Its aim is to evaluate the effectiveness and safety of the drug combination inavolisib and fulvestrant compared with the drug combination alpelisib and fulvestrant.

    It is aimed at patients with locally advanced or metastatic breast cancer. All patients who will participate in the study have previously undergone therapy based on cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and hormonal therapy. Study participants’ breast cancer must be hormone receptor positive (HR+), human epidermal growth factor receptor type 2 negative (HER2-), and must have a PIK3CA gene mutation.

    The aim of the study is to compare which drug combination – inavolisib and fulvestrant or alpelisib and fulvestrant – is more effective in the treatment of this type of breast cancer. This study also tries to assess what the side effects of both therapies are.

    Inavolisib and fulvestrant treatment involves administering inavolisib tablets once a day and fulvestrant injections at the beginning and during treatment cycles. An alternative treatment, i.e. alpelisib with fulvestrant, also involves daily use of alpelisib tablets and fulvestrant injections according to planned cycles.

    • Alpelisib
    • Fulvestrant
    • Inavolisib
  • Study of Tobemstomig and supportive medications for patients with advanced or metastatic triple-negative breast cancer

    The clinical trial is for patients with triple-negative breast cancer (TNBC) that is locally advanced, inoperable or metastatic (stage IV) and has not been previously treated. The study compares a new immune therapy, Tobemstomig (RO7247669), in combination with Nab-Paclitaxel, and Pembrolizumab.

    The aim of the study is to assess the effectiveness and safety of the therapy. Patients will be randomly assigned to one of two groups: in the first group, patients will receive Tobemstomig every three weeks and Nab-Paclitaxel for three weeks, followed by a week off. In the second group, patients will receive Pembrolizumab every three weeks and Nab-Paclitaxel for three weeks, followed by a week off. Therapies will be continued until disease progression or for a maximum of 24 months from the start of treatment.

    The study is aimed at adults aged 18 and over who are well enough to be eligible for treatment. The presence of appropriate markers in the tumor tissue is also required. Patients cannot participate in the study if they have ongoing infections, uncontrolled health problems, or are pregnant.

    • Tobemstomig
    • Pembrolizumab
    • nab-Paclitaxel
  • Study of INBRX-109 for patients with unresectable or metastatic conventional chondrosarcoma

    Conventional chondrosarcoma is a type of cancer that affects the bones. This clinical trial focuses on evaluating a new treatment for patients with unresectable (inoperable) or metastatic (spread to other parts of the body) conventional chondrosarcoma. The therapy being tested is called INBRX-109. INBRX-109 is an experimental drug, specifically a humanized antibody that targets a protein called death receptor 5 (DR5). The study aims to determine whether INBRX-109 can help patients who have this type of bone cancer.

    In this study, participants will be randomly assigned to one of two groups: one group will receive INBRX-109, and the other will receive a placebo. Neither the participants nor the researchers will know who is receiving the actual drug and who is receiving the placebo. This is known as a double-blind study. Participants will receive their assigned treatment through an intravenous infusion every three weeks. If the disease progresses, those in the placebo group will be allowed to switch to the INBRX-109 treatment.

    The primary goal of the study is to see how well INBRX-109 works in preventing the cancer from getting worse. The study will also look at overall survival rates, how long any responses to the treatment last, and the quality of life of the participants during the study. Safety and tolerability of INBRX-109 will also be evaluated by monitoring for any side effects. Participants will have regular visits and tests to check on their condition and the effects of the treatment. This clinical trial offers a potential new treatment option for patients with difficult-to-treat chondrosarcoma, aiming to improve their outcomes and quality of life.

    • INBRX-109
    • placebo
  • Study on the effectiveness and safety of DMX-200 for FSGS patients using ARB

    Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease where some parts of the kidneys become scarred, leading to kidney damage and protein loss in urine. This study involves a therapy using an experimental drug named DMX-200 (also known as repagermanium), which, when taken with a type of medication called an Angiotensin II Receptor Blocker (ARB), aims to halt the inflammation that contributes to chronic kidney disease.

    The study is designed to assess how well DMX-200 works and how safe it is in treating people with FSGS. It will compare the effects of DMX-200 with a placebo over a period of 104 weeks (about 2 years). Patients will be given either DMX-200 in capsule form to take twice daily or a placebo. Given the rarity of FSGS, the study will include both adults and adolescents aged 12 to 17 years.

    The study will start with a screening period to ensure all necessary assessments are completed. This will be followed by the main treatment phase, lasting 104 weeks. After this, there will be a 4-week follow-up period without treatment to observe any changes. Patients who complete this double-blind period and might benefit from continued treatment will enter an open-label extension phase. During this phase, participants will receive DMX-200 for an additional 2 years, also followed by a 4-week off-treatment period for further observation.

    The goal is to determine the effectiveness and long-term safety of DMX-200 for treating FSGS. The study aims to improve understanding and develop new treatments for this challenging kidney condition.

    • DMX-200
    • placebo
  • Testing BI 764198 for Kidney Disease (FSGS): A 4-Month Study

    This study is focused on individuals with a kind of kidney disease called Focal Segmental Glomerulosclerosis (FSGS). The purpose is to see if a drug named BI 764198 can improve kidney health for people with FSGS. There will be three different doses of BI 764198 tested in the study.

    Participants in the study will be divided into four groups randomly. Three groups will receive different doses of BI 764198, and one group will receive a placebo. The study will last about four months. For approximately three months, participants will take a BI 764198 capsule or placebo capsule daily.

    Participants will visit the study site around ten times. It is possible to participate from home, in which case a research nurse will visit for the study visits. Kidney health will be checked by analyzing urine samples that participants collect at home. The results will be compared between the different groups at the end of the study. Throughout the study, doctors will also regularly monitor the general health of participants.

    • BI 764198
    • placebo
  • Study of Barzolvolimab (CDX-0159) in Adult Patients with Eosinophilic Esophagitis

    This clinical study involves patients with Eosinophilic Esophagitis (EoE), a condition where a type of white blood cell, called eosinophils, builds up in the lining of the esophagus. This can lead to difficulty swallowing and other issues. The therapy being tested is barzolvolimab (CDX-0159).

    The goal of the study is to test the effectiveness and safety of barzolvolimab in adults with active EoE. There are two main groups in this study: one will receive barzolvolimab, and the other will receive a placebo, followed by barzolvolimab.

    Participants will receive treatment through subcutaneous (under the skin) injections every four weeks for 24 weeks. In the barzolvolimab group, patients will get 300 mg of the medication from the start. In the other group, patients will receive a placebo for the first 16 weeks and then switch to barzolvolimab for the remaining 8 weeks.

    The study will look at changes in the number of eosinophils and other cells in the esophagus, as well as symptoms like difficulty swallowing. Side effects and other health changes will be monitored throughout the study.

    • Placebo
    • barzolvolimab
  • Testing Tislelizumab and Spartalizumab for Various Cancers with High PD1 Levels

    This study focuses on the treatment of various types of cancer, including colorectal cancer, melanoma, anal carcinoma, mesothelioma, triple-negative breast cancer, lung adenocarcinoma, cholangiocarcinoma, cervical carcinoma, kidney clear cell carcinoma, stomach adenocarcinoma, esophageal adenocarcinoma, uterine adenocarcinoma, head and neck squamous cell carcinoma, sarcoma, lung squamous cell carcinoma, urothelial carcinoma, thyroid carcinoma, hepatocellular carcinoma, uveal melanoma, HER2-positive breast cancer, pancreatic adenocarcinoma, squamous esophageal carcinoma, epithelial ovarian cancer, uterine carcinosarcoma, small cell lung cancer, hormone receptor positive/HER2-negative breast cancer, lung adenocarcinoma with EGFR mutation or ALK translocation, colorectal adenocarcinoma, prostate adenocarcinoma, carcinoma of unknown primary, and other histologies.

    The therapy involves two drugs: Spartalizumab and Tislelizumab. Spartalizumab is administered at a dose of 400 mg intravenously every 28 days, while Tislelizumab is administered at a dose of 300mg intravenously every 28 days.

    The purpose of this study is to evaluate the effectiveness of these drugs in patients with tumors that express high levels of a protein called PD1 or lower levels in which PD1/PD-L1 inhibitors have been previously established to be effective. PD1 is a protein found on the surface of cells that helps keep the body’s immune responses in check and blocks cancer-fighting immune cells.

    The study is divided into three groups, called cohorts. Patients will first sign a consent form to allow a molecular test to determine the PD1 levels of their tumor. Patients with high PD1-expressing tumors will be placed into cohort 1 or cohort 3. Those with low PD1-expressing tumors, where the effectiveness of similar treatments has been previously established, will be placed into cohort 2.

    – Cohort 1 will receive Spartalizumab as monotherapy (single drug treatment).
    – Cohort 2, consisting of patients with PD1-low tumors, will also receive Spartalizumab as monotherapy.
    – Cohort 3 will receive Tislelizumab as monotherapy.

    Frequent evaluations will be conducted to monitor the patient’s response to the treatment. Participants will receive the drugs intravenously (through a vein) every 28 days and will be closely observed for any improvements or potential side effects.

    • Spartalizumab
    • Tislelizumab
  • Combining immunotherapy and chemoradiotherapy for Anal Cancer treatment

    Anal carcinoma, specifically squamous cell carcinoma of the anal canal, will be the focus of this study. Patients who have not previously received treatment for this type of cancer and are candidates for combined chemotherapy and radiation treatment will participate. This study will examine the effectiveness of adding immunotherapy drugs, Atezolizumab and Tiragolumab, to standard chemoradiotherapy. These drugs help the body’s immune system recognize and attack cancer cells. The main objective is to determine if this combination can achieve a complete response, meaning the cancer completely disappears according to certain medical evaluations.

    Throughout the study, patients will first receive two cycles of Atezolizumab and Tiragolumab along with chemoradiotherapy, which includes the chemotherapy drugs Cisplatin and 5-Fluorouracil, and a specific schedule of radiation therapy. After this initial phase, they will continue with Atezolizumab and Tiragolumab for an additional 24 weeks during a consolidation phase.

    Safety, the effectiveness of treatment, patients’ quality of life, and certain molecular biomarkers in the cancer and blood will be closely monitored throughout the study. Patients can stop the treatment if there are risks of progression, serious side effects, or based on decisions made by themselves or their doctors.

    This study hopes to provide greater insight into whether combining these immunotherapy drugs with standard treatment can improve outcomes for patients with localized squamous cell carcinoma of the anal canal.

    • Atezolizumab plus Tiraglolumab
  • Study of Povetacicept for treating autoimmune blood disorders

    This clinical study aims to evaluate the safety and potential benefits of a drug called povetacicept in adults with autoimmune cytopenias, specifically immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease. The study is open-label, meaning both the researchers and participants know what treatment is being administered. Participants will receive povetacicept through a subcutaneous injection approximately every four weeks for six months. There is also a possibility of extending the treatment for an additional six months. The primary goal is to monitor the type, incidence, severity, and seriousness of any adverse events from the first day of treatment through 30 days after the last dose. This study is designed to determine if povetacicept is safe and potentially beneficial in treating these autoimmune conditions.

    • povetacicept
  • A Study of Obexelimab for treating Warm Autoimmune Hemolytic Anemia

    Warm Autoimmune Hemolytic Anemia (wAIHA) is a condition where the body’s immune system attacks and destroys its own red blood cells. This study will examine whether obexelimab can help treat people with wAIHA. Obexelimab is a special type of treatment called a monoclonal antibody, which can target and potentially reduce the activity of some immune cells involved in this disease.

    Study participants will go through different stages. The first stage is a Safety and Dose Confirmation Run-In Period (SRP) lasting for six months. During this time, all participants will receive obexelimab through injections under the skin. This is followed by the Randomized Control Period (RCP), which also lasts for six months. In this stage, participants will be randomly divided into two groups: one group will continue to receive obexelimab, while the other group will receive a placebo.

    After these initial periods, participants will have the chance to continue receiving obexelimab in an Open Label Extension (OLE) period lasting up to a year. Throughout the study, participants will visit the study site for regular checks to ensure the treatment’s effectiveness and safety.

    • Obexelimab
  • Study of Elafibranor in the treatment of adult patients with Primary Biliary Cholangitis (PBC)

    The clinical trial is aimed at adult patients with confirmed primary cholangitis (PBC). Patients with this condition have an inadequate response or intolerance to ursodeoxycholic acid (UDCA), a drug used to treat PBC.

    Primary cholangitis is a disease that slowly progresses and leads to damage to the bile ducts in the liver. This causes a build-up of bile acids, which further damages the liver. As the disease progresses, scarring of the liver may develop (cirrhosis). PBC is also associated with numerous symptoms, such as itching and fatigue, and may lead to the need for a liver transplant.

    The study evaluates the effectiveness and safety of a drug called elafibranor at a dose of 80 mg daily. The study will compare elafibranor with a placebo, an inactive substance administered for control purposes. The main goal of the study is to test the effectiveness of elafibranor. The safety of long-term use of this medicine and its effect on symptoms such as itching and fatigue will also be checked.

    • Elafibranor

See more clinical trials in other cities in Spain: